SI Stock Forecast & Price Target

Shoulder Innovations is viewed favorably because its commercial-stage, capital-light model is compounding in a growing shoulder arthroplasty market, with Q2 revenue of $17.2M, 56.0% year over year growth, and FY26 sales guidance raised to $67M-$69M. Its differentiated portfolio already covers about 89% of surgeon needs, while recent launches such as the I-135 fracture stem, N-22 glenosphere, and Titanium Base Plate are lifting ASPs and expanding the addressable market by $200M+. Further upside comes from strong surgeon additions, durable gross margins, and a robotic platform targeted for FDA submission in 1H27, which could deepen workflow advantages and support faster long-term growth.

Shoulder Innovations is facing a cautious outlook because, despite 2Q26 revenue of about $17.2 million and unit growth of 48.9% Y/Y, its top-line expansion is still highly dependent on procedure mix and surgeon adoption, leaving ASPs vulnerable as reverse-shoulder cases moderate. Management’s FY26 guide of $67 million to $69 million implies growth, but the company itself flags lower 3Q26 seasonality, higher operating expenses as a share of sales in 3Q26, and 4Q26 ASP pressure from a lower proportion of reverse shoulder replacement procedures. The bear case is further reinforced by the risk that slower uptake from a smaller number of new surgeons, weaker shoulder market growth, or faster ASP degradation could undermine margin and revenue durability.